scholarly journals Evaluation of the LABGEO PT10 Point-Of-Care Testing Device: Comparison of Analyte Measurements in Capillary Whole Blood and Lithium Heparin Whole Blood Samples With Those in Central Laboratory

2016 ◽  
Vol 31 (3) ◽  
pp. e22050 ◽  
Author(s):  
Jinsook Lim ◽  
Hyunjin Kim ◽  
Sun Hoe Koo ◽  
Gye Cheol Kwon
Keyword(s):  
Whole Blood ◽  
Point Of Care ◽  
Testing Device ◽  
Central Laboratory ◽  
Point Of Care Testing ◽  
Blood Samples ◽  
Whole Blood Samples

The Variability of Results Between Point-of-Care Testing Glucose Meters and the Central Laboratory Analyzer

2006 ◽  
Vol 130 (10) ◽  
pp. 1527-1532
Author(s):  
Adil I. Khan ◽  
Yolanda Vasquez ◽  
Jacquelyn Gray ◽  
Frank H. Wians Jr ◽  
Martin H. Kroll
Keyword(s):  
Whole Blood ◽  
Point Of Care ◽  
Clinical Results ◽  
Central Laboratory ◽  
Point Of Care Testing ◽  
Blood Samples ◽  
Glucose Meter ◽  
Whole Blood Samples ◽  
Blood Specimens ◽  
Laboratory Analyzer

Abstract Context.—Point-of-care testing glucose meters are strongly recommended in the management of diabetes and are increasingly being used for making therapeutically important decisions. Thus, it is essential that their results correlate well with those of laboratory analyzers. Objectives.—To test the reliability of point-of-care testing glucose meters. Design.—Two studies were performed: (1), an in-house study comparing accuracy of point-of-care testing glucose meters with a reference analyzer using fresh whole blood specimens (2), a real-time comparison of (a) 2 successive glucose meter readings and (b) glucose meter reading to central laboratory analyzer reading. Setting.—(1), Seven glucose meters from 4 manufacturers were compared with the Yellow Springs YSI 2300 blood glucose analyzer using whole blood without preservative. (2), (a) Whole blood samples were read within 5 minutes of each other using Accu-Chek meters and (b) between a glucose meter and a Hitachi laboratory analyzer. Results.—(1) Within the Accu-Chek group of glucose meters, fresh, preservative-free whole blood samples showed the lowest bias. (2) At the hypoglycemic level, successive glucose meter readings agreed well, but there was considerable disagreement between glucose meter and central laboratory values. Because laboratory analyzers are of proven accuracy, they are used as the reference. In the glucose meter–central laboratory analyzer correlation, for both hypoglycemic and hyperglycemic values, readings in which the differences were greater than 10% occurred more than 61% of the time. In the hypoglycemic range, differences greater than 20% occurred 57% of the time. Conclusions.—One should scrutinize point-of-care testing glucose meter readings at the hypoglycemic and hyperglycemic levels and whenever possible to corroborate these clinical results with central laboratory analyzers.

Quality assuring HIV point of care testing using whole blood samples

Pathology ◽  
2016 ◽  
Vol 48 (5) ◽  
pp. 498-500 ◽  
Author(s):  
Raellene Dare-Smith ◽  
Tony Badrick ◽  
Philip Cunningham ◽  
Alison Kesson ◽  
Susan Badman
Keyword(s):  
Whole Blood ◽  
Point Of Care ◽  
Point Of Care Testing ◽  
Blood Samples ◽  
Whole Blood Samples

scholarly journals Hemolysis Rates in Whole Blood Samples for Blood Gas/Electrolyte Analysis by Point-of-Care Testing

2018 ◽  
Vol 3 (1) ◽  
pp. 144-145 ◽  
Author(s):  
Amanda Wilson ◽  
Maranna Sweeney ◽  
P L Mark Lynch ◽  
Maurice J O'Kane
Keyword(s):  
Whole Blood ◽  
Point Of Care ◽  
Blood Gas ◽  
Point Of Care Testing ◽  
Blood Samples ◽  
Whole Blood Samples

scholarly journals Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing

2001 ◽  
Vol 47 (4) ◽  
pp. 703-711 ◽  
Author(s):  
Timo Piironen ◽  
Martti Nurmi ◽  
Kerttu Irjala ◽  
Olli Heinonen ◽  
Hans Lilja ◽  
...  
Keyword(s):  
Physical Exercise ◽  
Prostate Specific Antigen ◽  
Whole Blood ◽  
Point Of Care ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Point Of Care Testing ◽  
Blood Samples ◽  
Whole Blood Samples

Abstract Background: The purpose of this study was to validate the use of whole-blood samples in the determination of circulating forms of prostate-specific antigen (PSA). Methods: Blood samples of hospitalized prostate cancer and benign prostatic hyperplasia patients were collected and processed to generate whole-blood and serum samples. Three different rapid two-site immunoassays were developed to measure the concentrations of total PSA (PSA-T), free PSA (PSA-F), and PSA-α1-antichymotrypsin complex (PSA-ACT) to detect in vitro changes in whole-blood samples immediately after venipuncture. The possible influence of muscle movement on the release of PSA from prostate gland was studied in healthy men by measuring the rapid in vitro whole-blood kinetics of PSA forms before and after 15 min of physical exercise on a stationary bicycle. Results: Rapid PSA-T, PSA-F, and PSA-ACT assays were designed using a 10-min sample incubation. No significant changes were detected in the concentrations of PSA-T, PSA-F, and PSA-ACT from the earliest time point of 12–16 min compared with measurements performed up to 4 h after venipuncture. Physical exercise did not influence the concentrations of the circulating forms of PSA. Hematocrit-corrected whole-blood values of PSA-T and PSA-F forms were comparable to the respective serum values. Calculation of the percentage of PSA-F (PSA F/T ratio × 100) was similar irrespective of the sample format used, i.e., whole blood or serum. Conclusions: We found that immunodetectable PSA forms are likely at steady state immediately after venipuncture, thus enabling the use of anticoagulated whole-blood samples in near-patient settings for point-of-care testing, whereas determinations of PSA (e.g., PSA-T, PSA-F, or PSA-ACT) performed within the time frame of the office visit would provide results equivalent to conventional analyses performed in serum.

European Concerted Action on Anticoagulation (ECAA): International Normalized Ratio Variability of CoaguChek and TAS Point-of-Care Testing Whole Blood Prothrombin Time Monitors

2002 ◽  
Vol 88 (12) ◽  
pp. 992-995 ◽  
Author(s):  
M. Keown ◽  
N. Chauhan ◽  
C. Shiach ◽  
A. M. H. P. van den Besselaar ◽  
A. Tripodi ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
Whole Blood ◽  
Point Of Care ◽  
International Normalized Ratio ◽  
Operator Technique ◽  
Concerted Action ◽  
Point Of Care Testing ◽  
Blood Samples ◽  
International Normalised Ratio ◽  
Whole Blood Samples

SummaryThe object was to assess the variability in displayed International Normalised Ratio (INR) between monitors of the same manufacture using whole blood samples from the same subjects. Two brands of monitor, CoaguChek Mini and the TAS PT-NC were tested.14 instruments of each brand were tested on the same day at the same laboratory by the same operator using identical blood samples to avoid between-centre differences in samples and operator technique. Whole blood samples from two normal donors and four coumarintreated patients were tested to assess between-instrument variability of INR.Results have been coded. There was a much wider dispersion of INR on Brand B than on Brand A. One Brand A instrument failed to give a result with one of the two whole blood samples from one patient. One Brand B monitor gave an aberrant result with one of the samples from a normal subject.On both brands of monitor, INR variability appeared to be due mainly to duplication differences rather than between-instrument variability on both normal and coumarin whole blood samples.

scholarly journals A Quantitative Immunochromatography Assay of Whole Blood Samples for Antigen-specific IgE—A New Method for Point of Care Testing for Allergens—

2005 ◽  
Vol 54 (3) ◽  
pp. 393-399 ◽  
Author(s):  
Tetsuya Ono ◽  
Kazuyuki Sugiyama ◽  
Takashi Kuroda ◽  
Masahide Kawamura ◽  
Shinsuke Arao ◽  
...  
Keyword(s):  
Whole Blood ◽  
Point Of Care ◽  
Specific Ige ◽  
New Method ◽  
Point Of Care Testing ◽  
Blood Samples ◽  
Whole Blood Samples

Development of a new point-of-care testing system for measuring white blood cell and C-reactive protein levels in whole blood samples

2014 ◽  
Vol 433 ◽  
pp. 145-149 ◽  
Author(s):  
Kazuhiko Kotani ◽  
Takaomi Minami ◽  
Toshiaki Abe ◽  
Junji Sato ◽  
Nobuyuki Taniguchi ◽  
...  
Keyword(s):  
Blood Cell ◽  
Whole Blood ◽  
Point Of Care ◽  
Testing System ◽  
Point Of Care Testing ◽  
C Reactive Protein ◽  
Blood Samples ◽  
Protein Levels ◽  
Reactive Protein ◽  
Whole Blood Samples

Monitoring of Coagulation during Hemorrhagic Surgery by Central Laboratory and Near-Patient Testing. Results of a Multicenter Study.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1043-1043
Author(s):  
Pierre A. Toulon ◽  
Yves Ozier ◽  
Annick Ankri ◽  
Marie-Helene Fleron ◽  
Genevieve Leroux ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Whole Blood ◽  
Capillary Tube ◽  
Point Of Care ◽  
Trauma Surgery ◽  
Control Sample ◽  
Fresh Frozen Plasma ◽  
Central Laboratory ◽  
Blood Samples ◽  
Arterial Blood

Abstract One of the critical issues in the monitoring of coagulation during surgery is the delay required to obtain results when tests are performed in a central laboratory. The CoaguChek ProDM (Roche Diagnostics) is a point-of-care (POC) coagulation analyzer designed to perform the measurement of clotting times such as the prothrombin time (PT) or the INR, and the activated partial thromboplastin time (APTT). So far, it has been mainly evaluated in the control of anticoagulation in patients on warfarin. A 45 μl-whole blood sample is disposed in the well of a specific 37°C-prewarmed single-use cartridge. It then circulates in a capillary tube coated with a specific agent. The test result is usually obtained in less than 5 min. The precision, evaluated as the “within-run” coefficient of variation (n=7), was found in the range from 3.2% to 7.3% depending of both the lyophilized whole blood control sample evaluated (normal or abnormal) and the clotting time performed. The aim of this multicenter study was to evaluate the performance of the CoaguChek ProDM in the monitoring of coagulation (PT and APTT) during hemorrhagic surgery. For that purpose, 78 patients undergoing surgical procedure (liver transplantation, liver resection, vascular and orthopedic/trauma surgery) were included in 3 centers after the study was approved by our Ethic Committee. Arterial blood samples were drawn at least 2 times: before the surgical incision and after a blood loss of 25% or more. Blood samples were simultaneously sent to the central laboratory and analyzed using the POC device. A total of 171 consecutive paired analyses were conducted. There was a very good agreement of the point-of-care-based monitoring of PT (sec) with the central laboratory monitoring (r=0.92, p<0.0001). However, the results were not identical, with significantly shorter clotting times (and lower ratios) obtained on the CoaguChek. It could be mentioned that, the difference was dramatically reduced when PT was expressed as the percentage, as it is usual in France. Comparison was less conclusive for APTT (r=0.82), with shorter clotting times (and lower ratios) again on the CoaguChek. Moreover, APTT measurement was found to be of limited interest in the studied population, particularly in the case of infusion of aprotinin which leaded to highly prolonged APTT (above the detection limits defined for the POC analyzer and for the central laboratory instrument, a STA analyzer). These results suggest that the CoaguChek ProDM allows an accurate measurement of PT in patients undergoing hemorrhagic surgical procedures. However, the results were not identical to that obtained from the central laboratory, suggesting that the transfusion algorithms would have to be adapted accordingly. One of the main advantages gained using POC testing is the ability to obtain results more rapidly. Actually, the turn-around time, defined as the elapsed time from blood sampling until availability of the results for the clinicians, was highly significantly shorter for the POC system than for the central laboratory (below 5 min vs. 60 min median value, range: 40->120 min). Finally, the clinical interest of such a point-of-care monitoring of coagulation deserves to be prospectively investigated, especially in connection with the amount of transfused fresh frozen plasma units.

Sign in / Sign up

Export Citation Format

Share Document